The Cardioprotective Effect of Vitamin D in Breast Cancer Patients Receiving Adjuvant Doxorubicin Based Chemotherapy.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The primary objective of this study was to investigate the potential protective effect of Vitamin D (Vit D) on DOX induced cardio toxicity (DIC) in early breast cancer patients receiving adjuvant DOX based chemotherapy (AC).

The secondary objective was to investigate the anti-inflammatory effect of Vit D by measuring serum IL-6 and its correlation with cardio toxicity.

Who Took Part

The study group was 150 women.

PubMed tags the participants as women only.

The cardio protective effect of Vit D was assessed by measuring serum levels of Lactate dehydrogenase (LDH), cardiac troponin T (cTnT), and anti-inflammatory Interleukin 6 (IL-6) at baseline, and after 4 cycles of AC in all study patients.

How the Study Was Run

The design is described as randomized.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

PubMed files the paper under topics including Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclophosphamide, Doxorubicin, Interleukin-6 and Vitamin D.

Author keywords: Breast cancer and Cardio toxicity.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 150 women.

The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Clinical breast cancer), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.